
Oncology Brothers: Practice-Changing Cancer Discussions
Oncology BrothersAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 20 minutes
- Latest episode:
About this show
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Covers: medical education, oncology, cancer treatment, lung cancer, hematology, clinical trials, genitourinary cancer, gastrointestinal cancer, cell therapy, continuing medical education
Show details and episodes come from the publisher's public feed at feed.podbean.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Hosted by two community oncologists, this podcast shares short interviews with cancer experts on new treatment data for clinicians. Recent episodes cover rectal cancer treatment, uncommon EGFR lung mutations, bladder cancer approval, and ESMO 2026 lung and GI cancer highlights.
Cosmos
Similar in subject
- The Fellow on Call: The Heme/Onc Podcast
Both cover: hematology, oncology, clinical trials - Two Onc Docs
Both cover: lung cancer, oncology, medical education - The Uromigos
Both cover: genitourinary cancer, oncology
Similar shows
- Harrison's PodClass: Internal Medicine Cases and Board Prep
- Plenary Session
- Ones Ready
- Optimal Health Daily - Fitness and Nutrition
- Optimal Living Daily - Personal Development and Self-Improvement
- Optimal Protein Podcast with Vanessa Spina
- Oral-Maxillofacial Surgery Insights
- Orgasmic Enlightenment with Kim Anami
Explore more
Episodes
Managing Toxicities of Pancreatic Cancer therapies: NALIRIFOX, FOLFIRINOX, Gem/Nab-Pac, Daraxonrasib
· 22 min
Welcome to the Oncology Brothers podcast! In this episode, we tackled the management of side effects associated with various treatment options for pancreatic cancer. Joined by Dr. Alok Khorana, from Cleveland Clinic and Dr. Weijing Sun, from the University of Kansas Medical Center, the discussion covered: - Key side effects of newer agents like daraxonrasib, liposomal irinotecan, gemcitabine, and nab-paclitaxel - The importance of maintaining quality of life for patients with pancreatic cancer - Insights on the use of leucovorin in treatment regimens and its impact on toxicity - Clinical pearls for managing common side effects such as diarrhea, neuropathy, and hand-foot syndrome - Prophylactic measures for minimizing adverse effects from treatments, particularly with daraxonrasib Join us as we explore the latest advancements in pancreatic cancer treatment and share valuable strategies for improving patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology! #PancreaticCancer, #SideEffectManagement, #QualityOfLife, #OncologyBrothers
Not rated yetChallenging Cases in Metastatic Pancreatic Cancer: Drs. Midhun Malla & Shafia Rahman
· 19 min
Welcome to the Oncology Brothers Podcast! In this episode, we discussed the complexities of pancreatic cancer treatment. Joined by two GI medical oncologists Dr. Midhun Malla, from the University of Alabama and Dr. Shafia Rahman, from the Ohio State University, where they discussed 2 challenging cases that highlighted the nuances of managing metastatic pancreatic adenocarcinoma. Episode Highlights: - Case 1: A 63-year-old gentleman with a pancreatic head mass and multiple liver lesions. The discussion focuses on the importance of liquid and solid tissue next-generation sequencing (NGS) testing, treatment options including NALIRIFOX, modified FOLFIRINOX, and gemcitabine plus nab-paclitaxel, and the implications of actionable mutations. - Case 2: A 71-year-old female with recurrent pancreatic cancer post-Whipple procedure and adjuvant gemcitabine treatment. The experts explore the role of daraxonrasib and the challenges of treatment sequencing after disease progression. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Join us as we navigate the latest treatment strategies, the significance of genetic testing, and the balance between efficacy and quality of life in pancreatic cancer care. #PancreaticCancer, #NGS, #NALIRIFOX, #FOLFIRINOX, #Daraxonrasib, #OncologyBrothers
Not rated yetESMO 2026 Breast Cancer Highlights: NATALEE, postMONARCH, TROPION-Breast02, INSPIRE-LM
· 24 min
Join us as we discussed the practice changing/informing studies presented at ESMO 2026. In this episode, we welcomed Dr. Javier Cortés, from Spain to discuss 4 key studies that are shaping the future of breast cancer treatment. Episode Highlights: - NATALEE: An update on adjuvant ribociclib for T2N0 with high-risk features and node-positive disease, including its impact on overall survival (OS) and distant disease-free survival (DDFS) - postMONARCH: Insights into the use of abemaciclib after prior CDK4/6 inhibitors in metastatic hormone receptor–positive breast cancer, focusing on progression-free survival (PFS) and OS outcomes - TROPION-Breast02: A look at the TNBC, highlighting the efficacy of datopotamab deruxtecan (Dato-DXd) in patients with central nervous system (CNS) metastasis - INSPIRE-LM: Exploring the promising results of intrathecal trastuzumab and pertuzumab for patients with leptomeningeal disease in HER2-positive metastatic breast cancer Tune in for an in-depth discussion on the latest advancements in breast cancer treatment and how these findings can be integrated into clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #BreastCancer, #ESMO2026, #CDK4-6i, #ADC, #OncologyBrothers
Not rated yetNeuroendocrine Tumor (NET) Management with Dr. Pamela Kunz - Treatment Algorithm
· 22 min
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the complex world of neuroendocrine tumors (NETs) with renowned specialist Dr. Pamela Kunz, from Yale School of Medicine. Join us as we explore: - The heterogeneous nature of neuroendocrine tumors, including differences in grade, origin, and functionality - Diagnostic workups and the role of imaging, including the use of ⁶⁸Ga-DOTATATE positron emission tomography (PET) scans - Treatment algorithms for both localized and metastatic NETs, focusing on somatostatin analogs, ¹⁷⁷Lu-DOTATATE, and other therapeutic options - The importance of shared decision-making in treatment approaches, especially for asymptomatic patients - Monitoring strategies and the evolving role of biomarkers like chromogranin A - Insights into high-grade neuroendocrine tumors and the potential for immunotherapy Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the current treatment landscape for neuroendocrine tumors. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #NeuroendocrineTumors, #NETs, #DOTATATE, #OncologyBrothers
Not rated yetRectal Cancer Treatment Algorithm - Multidisciplinary Approach with Drs. Madhu Eluri & Nina Sanford
· 19 min
In this segment of the treatment algorithms, we focused on rectal cancer treatment landscape with Dr. Nina Sanford, a radiation oncologist, and Dr. Madhu Eluri, MD, a medical oncologist. In this episode, we discussed: - The recent approval of dostarlimab for MSI-high rectal cancer and its implications for treatment - The importance of a multidisciplinary approach in managing stage II and III rectal cancer - The debate between total neoadjuvant treatment (TNT) versus the PROSPECT trial approach - The role of chemotherapy, radiation, and surgery in various risk categories of rectal cancer - How to monitor patients post-treatment and the significance of circulating tumor DNA (ctDNA) in decision-making - Insights into the management of metastatic rectal cancer and the potential for organ preservation Tune in for a comprehensive discussion that emphasizes the importance of biomarker-driven care and the evolving landscape of rectal cancer treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #RectalCancer, #MultiD, #MSI-H, #TNT, #OncologyBrothers
Not rated yetManagement of Uncommon EGFR Mutations in NSCLC: Dr. Susan Scott
· 17 min
In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q. Key topics discussed include: - The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations - Current treatment options for exon 20 insertions, including the combination of amivantamab and chemotherapy, and the promising data surrounding sunvozertinib - The challenges and considerations in treating patients with central nervous system (CNS) metastases and the role of systemic treatments versus localized therapies - Insights into the sequencing of treatments for rare EGFR mutations and the potential of datopotamab deruxtecan (Dato-DXd) in refractory settings Join us for an informative discussion that sheds light on the evolving landscape of targeted therapies for EGFR-mutated NSCLC. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes! #EGFRmNSCLC, #Exon20Insertion, #G719X, #S768I, #L861Q, #OncologyBrothers
Not rated yetDurvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA
· 25 min
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial. Join us as we explored: - The evolution of treatment standards for MIBC over the past 2 years - Key insights from the VOLGA trial, including study design, findings, and clinical implications - The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen - The balance between overtreatment and undertreatment in patient care - The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial
Not rated yetManagement of NSCLC with Common EGFR Mutations: Dr. Ben Levy
· 20 min
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib. Key topics covered include: - The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma - The shift from single-agent osimertinib to combination therapies and the implications for patient care - Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations - The importance of shared decision-making in oncology - Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations. #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
Not rated yetESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE
· 27 min
Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment. Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice: - DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) - SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy - KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile - PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers
Not rated yetESMO 2026 GI Cancer Highlights: HERIZON-GEA-01, CLARITY-GASTRIC01, AZUR1, CHECKMATE 8HW, HARMONi-GI1
· 23 min
Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies. Join us as we discussed: - HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment - CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings - AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery - CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer - HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast! #GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers
Not rated yetESMO 2026 Head & Neck Melanoma Highlights OrigAMI-4, INTerpath-001, STARBOARD
· 22 min
In this discussion we dived into the latest breakthroughs in head and neck cancer and melanoma from ESMO 2026. In this episode, we welcomed Dr. Ari Rosenberg from the University of Chicago, to discuss promising data on amivantamab for HPV-negative head and neck cancer, including its efficacy in frontline settings and important considerations for managing side effects. We also had the opportunity to talk to Dr. Sapna Patel from the University of Colorado, who shared insights on the INTerpath-001 study, exploring the role of personalized mRNA vaccines in the adjuvant setting for melanoma. Additionally, we discussed the STARBOARD trial, which investigated the triplet therapy of pembrolizumab, encorafenib, and binimetinib for BRAF V600E/K-positive melanoma patients. Tune in to hear our thoughts on how these findings may change clinical practice and the future of treatment options in oncology. Key Points - Amivantamab shows promising efficacy in HPV-negative head and neck cancer, particularly in the frontline setting, with a manageable toxicity profile that requires proactive side effect management. - Personalized mRNA vaccines in the adjuvant setting for melanoma represent a novel approach, with the INTerpath-001 study comparing this strategy against current standards of care. - The STARBOARD trial evaluates triplet therapy with pembrolizumab, encorafenib, and binimetinib in BRAF V600E/K-positive melanoma, with the potential to change clinical practice. - Logistical challenges, including vaccine manufacturing timelines and treatment coordination, remain important considerations for implementing these emerging therapies. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #HeadAndNeckCancer, #Melanoma, #mRNAVaccine, #OncologyBrothers
Not rated yetRCC Management in Localized & Metastatic Disease with Dr. Monty Pal - Rapid-Fire Rounds
· 18 min
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC). Join us as we dived into topics including: - The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan - Treatment strategies for oligometastatic disease and the use of radiation - Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and the implications of treatment breaks for patients on immuno-oncology (IO)–tyrosine kinase inhibitor (TKI) regimens - The evolving landscape of metastatic RCC, including the comparison of IO-IO versus IO-TKI combinations and the importance of patient-centered decision-making - The challenges and considerations in treating non–clear cell RCC, including the latest data on treatment options Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes! #RCC, #KidneyCancer, #AdjuvantTherapy, #IO-TKI, #OncologyBrothers
Not rated yetESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011
· 21 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology. Episode Highlights: - Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care. - Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the POTOMAC update and the role of durvalumab in high-risk, BCG-naive patients. - Prostate Cancer: An overview of the DASL-HiCaP and PROTEUS studies, highlighting the use of androgen receptor pathway inhibitors (ARPIs) in earlier lines of treatment and their impact on metastasis-free survival (MFS). - Renal Cell Carcinoma (RCC): Updates on KEYNOTE-564 and the LITESPARK studies, focusing on adjuvant therapies and the balance between efficacy and side effects. Join us as we cut through the noise and focus on what is practice-changing in the field of oncology. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to subscribe for more insights and updates from the world of cancer research! #ESMO2026, #GUOncology, #BladderCancer, #ProstateCancer, #KidneyCancer, #OncologyBrothers
Not rated yetMultiple Myeloma CAR-T Management - Partners in Practice
· 25 min
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers: - The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness - Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure - The importance of patient preparation and shared decision-making in treatment planning - The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion - An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity - The critical coordination efforts behind the scenes to ensure seamless patient care Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers
Not rated yetCAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations
· 22 min
Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan. Join us as we explore: - The basics of CAR T-cell therapy and the patient journey from referral to infusion - The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) - The importance of holding and bridging therapies to optimize patient outcomes - The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects - Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment! #CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers
Not rated yetRapid Fire Rounds - Thrombocytopenia Workup & Management with Dr. Ronak Mistry
· 27 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Ronak Mistry, a hematologist from Penn Medicine, for a rapid-fire round addressing common questions about thrombocytopenia. We dived into a variety of topics, including: - Differentiating between inherited thrombocytopenia and mild immune thrombocytopenia (ITP) - The role of steroids and bone marrow biopsy in diagnosis - Management of anticoagulation in patients with low platelet counts - Key distinctions between ITP, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP) - Recent updates to ITP guidelines and the incorporation of new treatment options - Thrombocytopenia in pregnancy and its management - Treatment options for chemotherapy-induced thrombocytopenia - Common medications that may contribute to thrombocytopenia Join us as we explore these important topics and provide practical insights for healthcare professionals dealing with thrombocytopenia in their clinical practice. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Thrombocytopenia, #ITP, #TTP, #aHUS, #OncologyBrothers
Not rated yetChallenging Cases in Small Cell Lung Cancer (SCLC) - Drs. Estela Rodriguez & Misty Shields
· 18 min
In this episode of the Oncology Brothers podcast, we dived into two challenging cases of small cell lung cancer (SCLC) to explore the latest supportive care options, the role of prophylactic cranial irradiation (PCI), and the sequencing of available treatments. We were joined by Dr. Estela Rodriguez from the University of Miami and Dr. Misty Shields from the Indiana University, as they discussed: - A young woman with limited-stage SCLC undergoing concurrent chemotherapy and radiation, and the management of treatment-related cytopenias - The implications of the recent MAVERICK trial comparing MRI surveillance to PCI and its impact on patient care - The evolving landscape of treatment options, including the use of trilaciclib and promising new therapies like tarlatamab and antibody-drug conjugates (ADCs) - Insights into maintenance therapy and the importance of close monitoring for brain metastases Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of small cell lung cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer care! #SmallCellLungCancer, #SCLC, #SupportiveCare, #MAVERICKtrial, #OncologyBrothers
Not rated yetWCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly
· 19 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026. We dived into five pivotal studies, including: - MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary - ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit - HARMONi: potential of ivonescimab, a PD-1 and VEGF bispecific antibody, in the treatment of EGFR-positive disease after progression on third-generation therapies - PAPILLON: discussion on the frontline treatment options for EGFR exon 20 insertion mutations, including the role of amivantamab and the anticipated approval of sunvozertinib - DESTINY-Lung04: an analysis of trastuzumab deruxtecan (T-DXd) in HER2-mutated lung cancer and its implications for treatment strategies Join us as we explore the latest advancements in lung cancer treatment and the importance of biomarker testing. Don't miss this informative episode packed with insights for oncologists and healthcare professionals! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Subscribe for more updates and discussions on the latest in oncology research and practice! #LungCancer, #WCLC2026, #Osimertinib, #Ivonescimab, #MAVERICK, #PAPILLON, #TDXd, #OncologyBrothers
Not rated yetManaging Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab
· 21 min
Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn. Join us as we discussed: - The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma - The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions - Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind - The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Tune in for an informative discussion that bridges the gap between research and clinical practice, ensuring that patients receive the best care possible. Don't forget to like, subscribe, and hit the notification bell for more episodes! #HER2positive, #UpperGICancer, #Zanidatamab, #Trastuzumab, #TDXd, #OncologyBrothers
Not rated yetUpper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner
· 26 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma. During our discussion we touched on: - The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments - The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery - The role of chemoradiation therapy for patients who are not surgical candidates and the nuances of managing residual disease - The importance of biomarker-driven treatment in metastatic disease, focusing on HER2 status, PD-L1 scores, and CLDN18.2 expression - The latest advancement, the approval of zanidatamab and clinical implications for treatment strategies - Management of side effects associated with these therapies and the importance of patient quality of life Whether you're a healthcare professional or someone interested in the latest in cancer care, this episode provides valuable insights into the complexities of treating upper GI cancers. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #UpperGICancer, #GastricCancer, #Zanidatamab, #Zolbetuximab, #OncologyBrothers
Not rated yet